About Adenosine Therapeutics
Adenosine Therapeutics is a Healthcare company based in Charlottesville (United States) founded in 1999, and was acquired by Timeline Logistics in August 2008. Small molecule therapeutics are developed targeting adenosine receptor subtypes. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its competitors include Portola Pharma, MyoKardia and Cellino; 3 of its 3 listed competitors have raised funding.
Company details
Adenosine Therapeutics develops novel pharmaceutical products that target adenosine receptor subtypes. Through an in-license agreement with the University of Virginia Patent Foundation, ATL was granted exclusive, worldwide rights to the Universitys adenosine-related patent portfolio, including apadenoson, developed as Stedivaze, a cardiac stress agent for use in diagnosis of coronary artery disease. Stedivaze was shepherded by ATL to the end of Phase II development before ATL sold substantially all its assets to Clinical Data (CLDA) in 2008. CLDA and its successors carried on development into late Phase III. At the end of 2012, ATL reacquired many of its programs, including Stedivaze. Stedivaze is now more than half way through Phase III trials.
- Headquarters Charlottesville, United States
- Stage Acquired
- SectorsHealthcare
- Website adenrx.com
- Acquired by Timeline Logistics (Aug 2008)
- Investors
- Acquired byTimeline Logistics
(Aug 2008)
Investors in Adenosine Therapeutics
Adenosine Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Timeline Logistics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Timeline Logistics is engaged in providing delivery and warehousing services in Texas. | 2005 | timelinelogistics.com | Houston, United States |
Investor details for Adenosine Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Adenosine Therapeutics
2 dated milestones of Adenosine Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Adenosine Therapeutics is founded.
- Exit Acquired by Timeline Logistics.
Competitors of Adenosine Therapeutics
Adenosine Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Portola Pharma, MyoKardia and Cellino.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies |
Detailed competitors of Adenosine Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Adenosine Therapeutics (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adenosine Therapeutics
Adenosine Therapeutics was founded in 1999.
Adenosine Therapeutics is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Adenosine Therapeutics develops novel pharmaceutical products that target adenosine receptor subtypes. Through an in-license agreement with the University of Virginia Patent Foundation, ATL was granted exclusive, worldwide rights to the Universitys adenosine-related patent portfolio, including apadenoson, developed as Stedivaze, a cardiac stress agent for use in diagnosis of coronary artery disease. Stedivaze was shepherded by ATL to the end of Phase II development before ATL sold substantially all its assets to Clinical Data (CLDA) in 2008. CLDA and its successors carried on development into late Phase III. At the end of 2012, ATL reacquired many of its programs, including Stedivaze. Stedivaze is now more than half way through Phase III trials.
Adenosine Therapeutics's top competitors include Cellino, MyoKardia and Portola Pharma.
Adenosine Therapeutics has 1 investor. Key investors include Timeline Logistics.
Yes. Adenosine Therapeutics was acquired by Timeline Logistics in August 2008.